SCHEMBL2923609

SCHEMBL2923609

CCOC(=O)c1cc(C(C)C)nn1-c1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
GAA P10253 1/20 0.50
THRB P10828 1/20 0.48
POLB P06746 3/20 0.46
KCNJ6 P48051 1/20 0.46
KCNJ5 P48544 1/20 0.46
KCNJ3 P48549 1/20 0.46
SCN9A Q15858 1/20 0.45
ELANE P08246 1/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.41
PDE4D Q08499 2/20 0.41
PDE4B Q07343 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25541024 0.88 ALDH1A1 (0.52) ALDH1A1GAAPOLBKCNJ6KCNJ5
SCHEMBL4431724 0.86 SLC5A1 (0.53) ALDH1A1GAAPOLBMAPTLMNA
SCHEMBL15518413 0.86 ALDH1A1 (0.50) ALDH1A1GAAPOLBSCN9AMAPT
SCHEMBL28648393 0.85 THRB (0.50) ALDH1A1THRBPOLBSCN9AELANE
SCHEMBL29655550 0.85 THRB (0.50) ALDH1A1THRBPOLBSCN9AELANE
SCHEMBL20503042 0.85 ALDH1A1 (0.55) ALDH1A1GAATHRBPOLBSCN9A
SCHEMBL28650933 0.84 THRB (0.49) ALDH1A1THRBPOLBSCN9AELANE
SCHEMBL15517487 0.84 ALDH1A1 (0.48) ALDH1A1GAAPOLBSCN9AMAPT
SCHEMBL28648734 0.83 THRB (0.48) ALDH1A1THRBPOLBSCN9AELANE
SCHEMBL2926900 0.83 ALDH1A1 (0.47) ALDH1A1GAAPOLBSCN9AELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481736-A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases Deciphera Pharmaceuticals, LLC. (US) 2012-08-01 EP disclosed
EP-2148677-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2010-02-03 EP disclosed
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 US disclosed
WO-2008131276-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES BRAF, RET, KIT ALDH1A1 1743/4885GAA 2558/4885THRB 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.